GlassScriptPhysician profile
Jason Michael Sharbaugh
NPI 1710195888
$12,288.39
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,827 · 2021: $3,145 · 2022: $2,655 · 2023: $2,665 · 2024: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286 · Education: $21.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.09 |
| Education | $21.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,592.18 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,269.15 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $796.08 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $791.63 | 2019-2023 | |
| Lilly USA, LLC | $713.25 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Teva Pharmaceuticals USA, INC. | $619.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $615.42 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Daiichi Sankyo INC. | $576.81 | 2019-2023 | Injectafer |
| Amgen INC. | $511.84 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $502.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.34 | 2019-2024 | Jardiance, Synjardy, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $455.45 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $398.69 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $396.17 | 2019-2023 | Gardasil 9, Belsomra, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $356.69 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Sharbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.